Fujirebio Diagnostics, Incorporated
$2.2M 10 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Orchard Therapeutics North America
Orchard Therapeutics North America reported $2,243,214.01 across General Payments, Research, and Ownership to 69 physicians and teaching hospitals across 77 transactions.
- $2.2M
- All-tracks total
- 77
- Transactions
- 69
- Recipients
- #425
- of 1,925 companies
Orchard Therapeutics North America reported $2,243,214.01 across all CMS Open Payments tracks (General + Research + Ownership) to 69 physicians and teaching hospitals in Program Year 2024 - ranking #425 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $14,046.59, averaging $32.5K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer orchard-therapeutics-north-america Orchard Therapeutics North America
$2.2M · #425/1,925 · 0.0% industry · PY2024
- TOT $2.2M
- RANK #425
- SHARE 0.0%
- TXN 77
- RCP 69
- CAT 3
- GEN $14.0K
- TOP1 28.6%
- PY 2024
Volume peers
Nearest volume peer: Fujirebio Diagnostics, Incorporated ($2.2M)
Orchard Therapeutics North America sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Orchard Therapeutics North America
Rank #425 of 1,925 companies in CMS Open Payments for 2024 belongs to Orchard Therapeutics North America, which reported $2,243,214.01 across 77 transactions to 69 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $29.1K per transaction and $32.5K per recipient.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $8.4K, accounting for 60.1% of this company's General Payments and 24 transactions.
General Payment Breakdown by Type
"Travel and Lodging" leads Orchard Therapeutics North America's 3-category general-payment breakdown at $8.4K, 60.1% of the reported total.
How Orchard Therapeutics North America divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $8.4K | 24 | 60.1% |
| Consulting Fee | $3.0K | 1 | 21.6% |
| Food and Beverage | $2.6K | 44 | 18.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $12,325.83 (87.7%) of $14,046.59 in this company's General Payments records across 17 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Orchard Therapeutics North America
The five named recipients with the highest reported General Payments from this company
- 1
Laura Adang
$4,018.76 across 18 reported transactions
- 2
Louis Cohen
$3,040.00 across 1 reported transactions
- 3
Jennifer Braun
$2,359.10 across 14 reported transactions
- 4
Lisa Tennyson Emrick
$1,746.40 across 8 reported transactions
- 5
Suhag Parikh
$1,161.57 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Orchard Therapeutics North America's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Orchard Therapeutics North America.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Orchard Therapeutics North America.
Showing 6 of 1,924 companies with CMS-reported payment data.
New World Medical,inc.
$2.2M 3,180 recipients
Compare payment profiles
Ceribell, Inc.
$2.3M 1,173 recipients
Compare payment profiles
Smarter Devices, LLC
$2.2M 0 recipients
Compare payment profiles
United Imaging Healthcare North America, Inc.
$2.2M 66 recipients
Compare payment profiles
Aimmune Therapeutics, Inc.
$2.3M 32,592 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.